BES_Mark.jpg
Bragar Eagel & Squire, P.C. Is Investigating Centuri, Medpace, Customers Bancorp, and Globus and Encourages Investors to Contact the Firm
30 août 2024 21h00 HE | Bragar Eagel & Squire
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Centuri Holdings, Inc...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Is Investigating Dril-Quip, LPL Financial, Methode, and Medpace and Encourages Investors to Contact the Firm
19 août 2024 21h00 HE | Bragar Eagel & Squire
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Dril-Quip, Inc. (NYSE:...
BES_Mark.jpg
MEDPACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Medpace Holdings, Inc. on Behalf of Medpace Stockholders and Encourages Investors to Contact the Firm
02 août 2024 21h00 HE | Bragar Eagel & Squire
NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Medpace Holdings, Inc....
DEINOVE prépare l’en
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé
31 janv. 2019 02h00 HE | Deinove
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé Le design de l’essai a été optimisé pour maximiser les chances de démontrer...
logo.jpg
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
31 janv. 2019 02h00 HE | Deinove
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in...